<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02502825</url>
  </required_header>
  <id_info>
    <org_study_id>GIRD201533</org_study_id>
    <nct_id>NCT02502825</nct_id>
  </id_info>
  <brief_title>Comparison of Methacholine Bronchial Provocation With Wright and Devilbiss646 Nebulizers</brief_title>
  <official_title>Comparison of 2-min Tidal Breathing Methacholine Bronchial Provocation With Wright and Devilbiss646 Nebulizers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Institute of Respiratory Disease</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Firestone Institute for Respiratory Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou Institute of Respiratory Disease</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the diagnostic validity (sensitivity and specificity)
      and evaluate the safety of 2-min Tidal Breathing methacholine bronchial provocation tests
      with the Wright and Devilbiss646 nebulizers in asthmatic in Guangzhou.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After screening,each asthmatic patient will visit the investigators' center 4 times.

      During the first week, the patient will be randomised to undergo methacholine bronchial
      challenge with Wright or Devilbiss 646 nebulizer on two separate days, which are at least 24
      hours but not more than 7 days apart.The above procedure will be repeated for each patient in
      one month. But the nebulizer will be selected in a reverse order.Provocative concentration
      induced a 20% decrease in forced expiratory volume in one second (PC20) will be calculated
      for each test. Record all the adverse events during the tests.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of the participants that tested positive to methacholine bronchial provocation with Wright or Devilbiss646 nebulizer</measure>
    <time_frame>5 minutes after each challenge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of Adverse Events during the methacholine bronchial provocation tests with Wright nebulizer and Devilbiss646 nebulizer</measure>
    <time_frame>during and until 5 minutes after each challenge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>asthma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>methacholine(0.031-16mg/ml) bronchial provocation tests. this is a crossover,normal-control study. nebulized with Wright nebulizer for 2 minutes with an output of 0.13ml/min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>methacholine(0.031-16mg/ml) bronchial provocation tests. this is a crossover,normal-control study. nebulized with Devilbiss646 nebulizer for 2 minutes with an output of 0.13ml/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>methacholine</intervention_name>
    <description>methacholine (0.03,0.06,0.125,0.5,1.0,2.0,4.0,8.0,16.0 mg/ml),Canada</description>
    <arm_group_label>asthma</arm_group_label>
    <arm_group_label>normal controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Wright Nebulizer</intervention_name>
    <description>nebulized for 2 minutes with an output of 0.13ml/min</description>
    <arm_group_label>asthma</arm_group_label>
    <arm_group_label>normal controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Devilbiss646 Nebulizer</intervention_name>
    <description>nebulized for 2 minutes with an output of 0.13ml/min</description>
    <arm_group_label>asthma</arm_group_label>
    <arm_group_label>normal controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of asthma;

          -  stable for more than 4 weeks with FEV1â‰¥65%pred

        Exclusion Criteria:

          -  exacerbation within 3 months;

          -  upper airway infections within 4 weeks;

          -  concomitant of hypertension or heart diseases;

          -  pregnancy;

          -  under immunotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinping Zheng</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Key Laboratory of Respiratory Disease; China Clinical Research Center of Respiratory Disease; First Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangzhou institute of respiratory disease</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2015</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Institute of Respiratory Disease</investigator_affiliation>
    <investigator_full_name>Jinping Zheng</investigator_full_name>
    <investigator_title>deputy director</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methacholine Chloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

